An Umbrella Study to Evaluate MLN1117 in Combination With Taxanes (Docetaxel or Paclitaxel) and Other Investigational Anticancer Agents for the Treatment of Patients With Previously Treated Advanced and Metastatic Gastric and Gastroesophageal Adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Alisertib (Primary) ; Serabelisib (Primary) ; TAK 659 (Primary) ; Docetaxel; Paclitaxel
- Indications Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 07 Mar 2017 Status changed from active, no longer recruiting to discontinued.
- 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.